论文部分内容阅读
目的探讨米索前列醇经直肠给药预防产后出血的临床疗效及安全性。方法采用随机平行对照法将2015年1月至2016年2月103例分娩产妇分为对照组51例及观察组52例,对照组口服给药预防,观察组选择直肠给药方式。观察并比较两组治疗后2、24 h内出血量、产后出血例数及不良反应发生率。结果观察组2、24 h内出血量及出血发生率均低于对照组(P<0.05);观察组不良反应发生率为3.85%,低于对照组的15.69%(P<0.05)。结论米索前列醇经直肠给药预防产后出血效果显著,安全性高,值得临床进一步推广及应用。
Objective To investigate the clinical efficacy and safety of misoprostol for rectal bleeding in preventing postpartum hemorrhage. Methods 103 cases of delivery women from January 2015 to February 2016 were divided into control group (n = 51) and observation group (n = 52) by randomized parallel control method. The control group was given oral prophylaxis and the observation group was given rectal dosing. The amount of bleeding, the number of postpartum hemorrhage and the incidence of adverse reactions were observed and compared within 2 and 24 hours after treatment. Results The bleeding rate and bleeding rate in observation group were lower than those in control group (P <0.05) in 2,24 h. The incidence of adverse reactions in observation group was 3.85%, which was lower than that in control group (15.69%, P <0.05). Conclusion The misoprostol is effective in preventing postpartum hemorrhage by rectal administration. It has high safety and deserves to be further popularized and applied clinically.